Summary

The stable isotope labeled compounds market was valued at $291.82 million in 2023 and is estimated to reach $420.1 million by 2035, exhibiting a CAGR of 3.1% from 2024 to 2035. Stable isotope-labeled compounds are molecules where one or more atoms are replaced with non-radioactive isotopes, such as carbon-13 (^13C), nitrogen-15 (^15N), deuterium (^2H), and others. These isotopes are chemically identical to their naturally occurring counterparts but differ in atomic mass, allowing them to be tracked without emitting radiation. Widely used in research and industrial applications, they play a crucial role in studying metabolic pathways, drug development, and environmental processes. Their non-radioactive nature makes them safe for use in both biological and chemical analyses, providing valuable insights into molecular behavior, reaction mechanisms, and interactions at a detailed level.

The growth of the stable isotope-labeled compounds market is significantly influenced by a range of interconnected factors that enhance its utility across various fields. The rise in demand for advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) plays a pivotal role. These techniques rely majorly on stable isotope-labeled compounds to achieve precise measurements and high-resolution analysis, thus driving their adoption. The need for accurate and reliable analytical tools increases, as research and diagnostic applications become sophisticated, further fueling market growth. In addition, the increase in application of stable isotope-labeled compounds in environmental studies highlights their versatility. These compounds are used to trace pollutants and monitor environmental changes, providing crucial data for regulatory and conservation efforts. This application drives the growing importance of stable isotope-labeled compounds in addressing global environmental challenges, thus fostering the market growth.

The expansion of clinical trials and proteomics studies represents another crucial driver. Stable isotope-labeled compounds are essential for understanding drug metabolism and the complex interactions within biological systems. In clinical trials, they help in tracing the metabolic pathways of new drugs, while in proteomics, they enable precise protein quantification and tracking. This growth in clinical and proteomics applications reflects the increasing reliance on these compounds for advancing medical research and personalized medicine.

Moreover, the rise in awareness and adoption of stable isotope-labeled compounds among researchers and clinicians is a key factor driving the market growth. There is an increase in the usage of these compounds as researchers and clinicians become familiar with the benefits associated with them, including their ability to enhance accuracy and reliability in various studies. This growing recognition of the value of stable isotope-labeled compounds further contributes to their increasing demand across diverse scientific and clinical fields, creating a synergistic effect that drives the overall market growth.
The stable isotope-labeled compounds market is segmented into type, application, end user, and region. On the basis of type, the market is segmented into Deuterium, Carbon-13, Oxygen-18, Nitrogen-15, and others. On the basis of application, the market is classified into research, clinical diagnostics, and other. The research segment is further divided into biomedical research, pharma research, and others. On the basis of end user, the market is categorized into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostic centers, and other end users. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Merck KGaA, Otsuka Holdings Co., Ltd., Entegris, Omicron Biochemicals, Inc., Shimadzu Corporation, Nippon Sanso Holding Corporation, Vivan Life Sciences, BOC Sciences, Silantes, and Symeres. The key players have adopted product launch, geographical expansion, partnership, and agreement as the key strategies to expand their product portfolio.

Key Benefits For Stakeholders
●
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stable isotope labeled compounds market analysis from 2023 to 2035 to identify the prevailing stable isotope labeled compounds market opportunities.
●
The market research is offered along with information related to key drivers, restraints, and opportunities.
●
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●
In-depth analysis of the stable isotope labeled compounds market segmentation assists to determine the prevailing market opportunities.
●
Major countries in each region are mapped according to their revenue contribution to the global market.
●
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●
The report includes the analysis of the regional as well as global stable isotope labeled compounds market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Patient/epidemiology data at country, region, global level
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Expanded list for Company Profiles
● Historic market data
● SWOT Analysis
Key Market Segments
By Type
● Deuterium
● Carbon 13
● Oxygen 18
● Nitrogen15
● Other
By Application
● Research
○ Type
○ Biomedical Research
○ Pharma Research
○ Others
● Clinical Diagnostics
● Others
By End User
● Pharmaceutical and Biotechnology Companies
● Academic and Research Institutes
● Hospitals and Diagnostic Centers
● Others
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ South Africa,
○ Saudi Arabia
○ Rest of LAMEA
● Key Market Players
○ BOC Sciences
○ Entegris
○ Merck KGaA
○ NIPPON SANSO HOLDINGS CORPORATION
○ Omicron Biochemicals, Inc.
○ Otsuka Holdings Co., Ltd.
○ Shimadzu Corporation
○ Silantes
○ Symeres
○ VIVAN Life Sciences

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in Cancer Prevalence and Advancements in Research
3.4.1.2. Growing Government Funding and Support
3.4.1.3. Rise in adoption of strategies by the key players
3.4.2. Restraints
3.4.2.1. High Production Costs and Technical Complexity
3.4.3. Opportunities
3.4.3.1. Growth Opportunity in emerging countries
CHAPTER 4: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Deuterium
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Carbon 13
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Oxygen 18
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Nitrogen15
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Other
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Research
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Research Stable Isotope Labeled Compounds Market by Type
5.3. Clinical Diagnostics
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pharmaceutical and Biotechnology Companies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Academic and Research Institutes
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Hospitals and Diagnostic Centers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: STABLE ISOTOPE LABELED COMPOUNDS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa,
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Saudi Arabia
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Merck KGaA
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Otsuka Holdings Co., Ltd.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Entegris
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Omicron Biochemicals, Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Shimadzu Corporation
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Silantes
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. VIVAN Life Sciences
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. BOC Sciences
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Symeres
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. NIPPON SANSO HOLDINGS CORPORATION
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance